Ipsen Pharma — Sponsor Intelligence | 16 EU Trials

Filter these 16 trials by condition, phase, country and more.

Open in Search →

16 Registered trials

5 Recruiting

11 Completed trials

16 Countries active

14 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I (Other)

Phase I (FiH)

Phase III: 5 Phase II/III: 1 Phase II: 2 Phase IV: 1 Phase I (Other): 2 Phase I (FiH): 4 Other: 1

100%

11 of 11 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Primary biliary cholangitis 2 Alagille syndrome 1 Metastatic neoplasm 1 Head and neck cancer 1 Colorectal cancer 1 Renal cell carcinoma 1

Top IMPs

ELAFIBRANOR 4 ODEVIXIBAT 2 BOTULINUM TOXIN TYPE A 1 BOTULINUM TOXIN TYPE A - HAEMAGGLUTININ COMPLEX 1 CABOZANTINIB 1 FLUOROURACIL 1 GEMCITABINE 1 IPN01194 1 IPN01195 1 IPN01203 1 IPN60300 1 IRINOTECAN 1

All trials

16 total

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adult… Recruiting

2025-522184-15-00 Phase I (FiH) 2 countries IPN01203
A study to assess the safety, tolerability, pharmacokinetic, pharmacodynamic, immunogenicity and antitumour activity of IPN60300 in adults w… Recruiting

2025-522139-33-00 Phase I (FiH) 2 countries IPN60300
A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours Recruiting

2024-519184-18-00 Phase I (FiH) 3 countries IPN01195
A Long-Term Study of Elafibranor in Adult Participants with Primary Biliary Cholangitis (ELFIDENCE) Recruiting

2023-505251-43-00 Phase III 14 countries ELAFIBRANOR
An extension study to evaluate the long-term efficacy and safety of odevixibat (A4250) in children with biliary atresia (BOLD-EXT) Recruiting

2022-501090-39-00 Phase III 8 countries ODEVIXIBAT
A Study of Elafibranor in Adults with Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid Ended

2024-510695-20-00 Phase III 7 countries ELAFIBRANOR
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours Ended

2023-506228-10-00 Phase I (FiH) 2 countries IPN01194
A study to assess safety and efficacy of Elafibranor in Adult Participants with Primary Sclerosing Cholangitis (PSC) Ended

2024-511370-72-00 Phase II 4 countries ELAFIBRANOR
A long term Investigation of the Safety and Efficacy of Odevixibat in Patients with Alagille syndrome Ended

2023-509028-17-00 Phase III 6 countries ODEVIXIBAT
A Double-blind Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80… Ended

2024-512232-30-00 Phase II/III 5 countries ELAFIBRANOR
A Mass Balance Study of [14C]-IPN60250 in Healthy Adult Participants Ended

2024-515195-12-00 Phase I (Other) 1 country
A study to assess the effect of gemfibrozil, itraconazole and phenytoin on levels of IPN60250 in the blood of healthy adult participant. Ended

2024-513891-16-00 Phase I (Other) 1 country
A study to compare Onivyde manufactured at two different production sites in adult participants with advanced cancer in the pancreas Ended

2024-516760-28-00 4 countries
A Study to Compare the Safety and Efficacy of Dysport® and Botox® in Adults with Upper Limb Spasticity Ended

2023-509196-16-00 Phase IV 1 country BOTULINUM TOXIN TYPE A; BOTULINUM TOXIN TYPE A - HAEMAGGLUTININ COMPLEX
Study to compare 2 chemotherapy, one with Irinotecan liposome injection in addition to combination of chemotherapy and one with standard che… Ended

2024-518303-21-00 Phase III 1 country FLUOROURACIL; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PACLITAXEL ALBUMIN-BOUND
Open-Label Study of Cabozantinib as 2nd Line Treatment in Subjects with Unresectable, Locally Advanced or Metastatic Renal Cell Carcinoma wi… Ended

2024-514479-16-00 Phase II 2 countries CABOZANTINIB

Showing 1–16 of 16 trials

← All sponsors A–Z